nivolumab,relatlimab
bms
['melanoma', 'melsm', '047 ,(-nct047),(-0.047%),(-2047)', 'relativity,047', 'thanks']
a huge thanks to , of , for talking with us at #asco23 about 2-year results from relativity-047 trial in melanoma! see our site for more from the meeting. #melsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.